Skip to main content
Top
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Liposarcoma | Research

Identification of NINJ1 as a novel prognostic predictor for retroperitoneal liposarcoma

Authors: Yu Zhao, Da Qin, Xiangji Li, Tiange Wang, Tong Zhang, Xiaosong Rao, Li Min, Zhiyi Wan, Chenghua Luo, Mengmeng Xiao

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Background

Retroperitoneal liposarcoma (RPLS) is known for its propensity for local recurrence and short survival time. We aimed to identify a credible and specific prognostic biomarker for RPLS.

Methods

Cases from The Cancer Genome Atlas (TCGA) sarcoma dataset were included as the training group. Co-expression modules were constructed using weighted gene co-expression network analysis (WGCNA) to explore associations between modules and survival. Survival analysis of hub genes was performed using the Kaplan–Meier method. In addition, independent external validation was performed on a cohort of 135 Chinese RPLS patients from the REtroperitoneal SArcoma Registry (RESAR) study (NCT03838718).

Results

A total of 19 co-expression modules were constructed based on the expression levels of 26,497 RNAs in the TCGA cohort. Among these modules, the green module exhibited a positive correlation with overall survival (OS, p = 0.10) and disease-free survival (DFS, p = 0.06). Gene set enrichment analysis showed that the green module was associated with endocytosis and soft-tissue sarcomas. Survival analysis demonstrated that NINJ1, a hub gene within the green module, was positively associated with OS (p = 0.019) in the TCGA cohort. Moreover, in the validation cohort, patients with higher NINJ1 expression levels displayed a higher probability of survival for both OS (p = 0.023) and DFS (p = 0.012). Multivariable Cox analysis further confirmed the independent prognostic significance of NINJ1.

Conclusions

We here provide a foundation for the establishment of a consensus prognostic biomarker for RPLS, which should not only facilitate medical treatment but also guide the development of novel targeted drugs.
Appendix
Available only for authorised users
Literature
2.
go back to reference Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011: 483154.CrossRefPubMed Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011: 483154.CrossRefPubMed
3.
go back to reference Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381–91.CrossRefPubMedPubMedCentral Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381–91.CrossRefPubMedPubMedCentral
4.
go back to reference Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238:358–70 (discussion 370-351).CrossRefPubMedPubMedCentral Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238:358–70 (discussion 370-351).CrossRefPubMedPubMedCentral
5.
go back to reference Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, Lahat G, Strauss DC, Gonzalez R, Ahuja N, et al. Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: a study and novel nomogram from TARPSWG. Clin Cancer Res. 2019;25:2664–71.CrossRefPubMed Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, Lahat G, Strauss DC, Gonzalez R, Ahuja N, et al. Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: a study and novel nomogram from TARPSWG. Clin Cancer Res. 2019;25:2664–71.CrossRefPubMed
6.
go back to reference MacNeill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, et al. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group. Cancer. 2017;123:1971–8.CrossRefPubMed MacNeill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, et al. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group. Cancer. 2017;123:1971–8.CrossRefPubMed
7.
go back to reference Gronchi A, Miceli R, Allard MA, Callegaro D, Le Péchoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, et al. Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection. Ann Surg Oncol. 2015;22:1447–54.CrossRefPubMed Gronchi A, Miceli R, Allard MA, Callegaro D, Le Péchoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, et al. Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection. Ann Surg Oncol. 2015;22:1447–54.CrossRefPubMed
8.
go back to reference Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, Duggan MC, Bupathi M, Brock GN, Millis SZ, et al. Degree of MDM2 amplification affects clinical outcomes in dedifferentiated liposarcoma. Oncologist. 2019;24:989–96.CrossRefPubMedPubMedCentral Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, Duggan MC, Bupathi M, Brock GN, Millis SZ, et al. Degree of MDM2 amplification affects clinical outcomes in dedifferentiated liposarcoma. Oncologist. 2019;24:989–96.CrossRefPubMedPubMedCentral
9.
go back to reference Lou Y, Ma Y, Li H, Song Y, Zhang X, Lin H, Zhang X, Ling J. High expression of fibroblast growth factor-21 in liposarcoma patients indicated better prognosis and less recurrence. Biochem Biophys Res Commun. 2018;503:1130–3.CrossRefPubMed Lou Y, Ma Y, Li H, Song Y, Zhang X, Lin H, Zhang X, Ling J. High expression of fibroblast growth factor-21 in liposarcoma patients indicated better prognosis and less recurrence. Biochem Biophys Res Commun. 2018;503:1130–3.CrossRefPubMed
10.
go back to reference Loria R, Laquintana V, Bon G, Trisciuoglio D, Covello R, Amoreo CA, Ferraresi V, Zoccali C, D’Incalci M, Biagini R, Falcioni R. 1689PHMGA1 is a new biomarker of liposarcoma progression. Ann Oncol. 2017;28:v591.CrossRef Loria R, Laquintana V, Bon G, Trisciuoglio D, Covello R, Amoreo CA, Ferraresi V, Zoccali C, D’Incalci M, Biagini R, Falcioni R. 1689PHMGA1 is a new biomarker of liposarcoma progression. Ann Oncol. 2017;28:v591.CrossRef
11.
go back to reference Tajima T, Kito F, Yoshida A, Kawai A, Kondo T. Calreticulin as a novel potential metastasis-associated protein in myxoid liposarcoma, as revealed by two-dimensional difference gel electrophoresis. Proteomes. 2019;7:13.CrossRefPubMedPubMedCentral Tajima T, Kito F, Yoshida A, Kawai A, Kondo T. Calreticulin as a novel potential metastasis-associated protein in myxoid liposarcoma, as revealed by two-dimensional difference gel electrophoresis. Proteomes. 2019;7:13.CrossRefPubMedPubMedCentral
12.
go back to reference Renner M, Wolf T, Meyer H, Hartmann W, Penzel R, Ulrich A, Lehner B, Hovestadt V, Czwan E, Egerer G, et al. Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biol. 2013;14: r137.CrossRefPubMedPubMedCentral Renner M, Wolf T, Meyer H, Hartmann W, Penzel R, Ulrich A, Lehner B, Hovestadt V, Czwan E, Egerer G, et al. Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biol. 2013;14: r137.CrossRefPubMedPubMedCentral
13.
go back to reference Aoyama T, Takasawa A, Takasawa K, Ono Y, Emori M, Murata M, Hayasaka T, Fujitani N, Osanai M, Yamashita T, et al. Identification of coiled-coil domain-containing protein 180 and leucine-rich repeat-containing protein 4 as potential immunohistochemical markers for liposarcoma based on proteomic analysis using formalin-fixed, paraffin-embedded tissue. Am J Pathol. 2019;189:1015–28.CrossRefPubMed Aoyama T, Takasawa A, Takasawa K, Ono Y, Emori M, Murata M, Hayasaka T, Fujitani N, Osanai M, Yamashita T, et al. Identification of coiled-coil domain-containing protein 180 and leucine-rich repeat-containing protein 4 as potential immunohistochemical markers for liposarcoma based on proteomic analysis using formalin-fixed, paraffin-embedded tissue. Am J Pathol. 2019;189:1015–28.CrossRefPubMed
14.
go back to reference Zhang Y, Tong H, He J, Shao Y, Guo X, Zhuang R, Yang J, Liu J, Ding Y, Liu W, et al. Linc00423 as a tumor suppressor in retroperitoneal liposarcoma via activing MAPK signaling pathway through destabilizing of NFATC3. Cell Death Dis. 2019;10:430.CrossRefPubMedPubMedCentral Zhang Y, Tong H, He J, Shao Y, Guo X, Zhuang R, Yang J, Liu J, Ding Y, Liu W, et al. Linc00423 as a tumor suppressor in retroperitoneal liposarcoma via activing MAPK signaling pathway through destabilizing of NFATC3. Cell Death Dis. 2019;10:430.CrossRefPubMedPubMedCentral
15.
go back to reference Mazzu YZ, Hu Y, Soni RK, Mojica KM, Qin LX, Agius P, Waxman ZM, Mihailovic A, Socci ND, Hendrickson RC, et al. miR-193b-regulated signaling networks serve as tumor suppressors in liposarcoma and promote adipogenesis in adipose-derived stem cells. Cancer Res. 2017;77:5728–40.CrossRefPubMed Mazzu YZ, Hu Y, Soni RK, Mojica KM, Qin LX, Agius P, Waxman ZM, Mihailovic A, Socci ND, Hendrickson RC, et al. miR-193b-regulated signaling networks serve as tumor suppressors in liposarcoma and promote adipogenesis in adipose-derived stem cells. Cancer Res. 2017;77:5728–40.CrossRefPubMed
16.
go back to reference Cui L, Tian X, Yan L, Guan X, Dong B, Zhao M, Lv A, Liu D, Wu J, Hao C. Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: bioinformatics analysis and clinicopathological evidence. Int J Med Sci. 2022;19:1977–88.CrossRefPubMedPubMedCentral Cui L, Tian X, Yan L, Guan X, Dong B, Zhao M, Lv A, Liu D, Wu J, Hao C. Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: bioinformatics analysis and clinicopathological evidence. Int J Med Sci. 2022;19:1977–88.CrossRefPubMedPubMedCentral
17.
go back to reference Xu C, Yan L, Guan X, Wang Z, Wu J, Lv A, Liu D, Liu F, Dong B, Zhao M, et al. Tsp2 facilitates tumor-associated fibroblasts formation and promotes tumor progression in retroperitoneal liposarcoma. Int J Biol Sci. 2022;18:5038–55.CrossRefPubMedPubMedCentral Xu C, Yan L, Guan X, Wang Z, Wu J, Lv A, Liu D, Liu F, Dong B, Zhao M, et al. Tsp2 facilitates tumor-associated fibroblasts formation and promotes tumor progression in retroperitoneal liposarcoma. Int J Biol Sci. 2022;18:5038–55.CrossRefPubMedPubMedCentral
18.
go back to reference Nezu Y, Hagiwara K, Yamamoto Y, Fujiwara T, Matsuo K, Yoshida A, Kawai A, Saito T, Ochiya T. miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. Oncogene. 2016;35:6177–88.CrossRefPubMedPubMedCentral Nezu Y, Hagiwara K, Yamamoto Y, Fujiwara T, Matsuo K, Yoshida A, Kawai A, Saito T, Ochiya T. miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. Oncogene. 2016;35:6177–88.CrossRefPubMedPubMedCentral
19.
go back to reference Costa-Pinheiro P, Montezuma D, Henrique R, Jerónimo C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 2015;7:1003–15.CrossRefPubMed Costa-Pinheiro P, Montezuma D, Henrique R, Jerónimo C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 2015;7:1003–15.CrossRefPubMed
20.
go back to reference Network CGAR. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171:950-965.e928.CrossRef Network CGAR. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171:950-965.e928.CrossRef
21.
go back to reference Li T, Wang W, Gong S, Sun H, Zhang H, Yang AG, Chen YH, Li X. Genome-wide analysis reveals TNFAIP8L2 as an immune checkpoint regulator of inflammation and metabolism. Mol Immunol. 2018;99:154–62.CrossRefPubMedPubMedCentral Li T, Wang W, Gong S, Sun H, Zhang H, Yang AG, Chen YH, Li X. Genome-wide analysis reveals TNFAIP8L2 as an immune checkpoint regulator of inflammation and metabolism. Mol Immunol. 2018;99:154–62.CrossRefPubMedPubMedCentral
22.
go back to reference Liu B, Huang Y, Sun Y, Zhang J, Yao Y, Shen Z, Xiang D, He A. Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep. 2016;6:39862.CrossRefPubMedPubMedCentral Liu B, Huang Y, Sun Y, Zhang J, Yao Y, Shen Z, Xiang D, He A. Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep. 2016;6:39862.CrossRefPubMedPubMedCentral
23.
go back to reference Liu G, Ke LC, Sun SR. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: a meta-analysis. Medicine (Baltimore). 2018;97: e12176.CrossRefPubMed Liu G, Ke LC, Sun SR. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: a meta-analysis. Medicine (Baltimore). 2018;97: e12176.CrossRefPubMed
24.
go back to reference Lee HJ, Ahn BJ, Shin MW, Choi JH, Kim KW. Ninjurin1: a potential adhesion molecule and its role in inflammation and tissue remodeling. Mol Cells. 2010;29:223–7.CrossRefPubMed Lee HJ, Ahn BJ, Shin MW, Choi JH, Kim KW. Ninjurin1: a potential adhesion molecule and its role in inflammation and tissue remodeling. Mol Cells. 2010;29:223–7.CrossRefPubMed
25.
go back to reference Verma M. The role of epigenomics in the study of cancer biomarkers and in the development of diagnostic tools. Adv Exp Med Biol. 2015;867:59–80.CrossRefPubMed Verma M. The role of epigenomics in the study of cancer biomarkers and in the development of diagnostic tools. Adv Exp Med Biol. 2015;867:59–80.CrossRefPubMed
26.
go back to reference Li YJ, Yang X, Zhang WB, Yi C, Wang F, Li P. Clinical implications of six inflammatory biomarkers as prognostic indicators in Ewing sarcoma. Cancer Manag Res. 2017;9:443–51.CrossRefPubMedPubMedCentral Li YJ, Yang X, Zhang WB, Yi C, Wang F, Li P. Clinical implications of six inflammatory biomarkers as prognostic indicators in Ewing sarcoma. Cancer Manag Res. 2017;9:443–51.CrossRefPubMedPubMedCentral
27.
go back to reference Song F, Yi Y, Li C, Hu Y, Wang J, Smith DE, Jiang H. Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage. Cell Death Dis. 2018;9:770.CrossRefPubMedPubMedCentral Song F, Yi Y, Li C, Hu Y, Wang J, Smith DE, Jiang H. Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage. Cell Death Dis. 2018;9:770.CrossRefPubMedPubMedCentral
28.
go back to reference Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007;81:584–92.CrossRefPubMed Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007;81:584–92.CrossRefPubMed
Metadata
Title
Identification of NINJ1 as a novel prognostic predictor for retroperitoneal liposarcoma
Authors
Yu Zhao
Da Qin
Xiangji Li
Tiange Wang
Tong Zhang
Xiaosong Rao
Li Min
Zhiyi Wan
Chenghua Luo
Mengmeng Xiao
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-01016-x

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine